Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

被引：37
作者：
Lin, Ting-Ting [1 ]
Chen, Ye-Hui [1 ]
Wu, Yu-Peng [1 ]
Chen, Shao-Zhan [1 ]
Li, Xiao-Dong [1 ]
Lin, Yun-Zhi [1 ]
Chen, Shao-Hao [1 ]
Zheng, Qing-Shui [1 ]
Wei, Yong [1 ]
Xu, Ning [1 ]
Xue, Xue-Yi [1 ]
机构：
[1] Fujian Med Univ, Affiliated Hosp 1, Dept Urol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China
来源：
JOURNAL OF CANCER | 2019年 / 10卷 / 22期
关键词：
metastatic prostate cancer; androgen deprivation therapy; castration-resistant prostate cancer; progression-free survival; risk factors; ANDROGEN DEPRIVATION THERAPY; SURVIVAL; MEN; BIOMARKERS; DIAGNOSIS; LEVEL; TRIAL; TIME;
D O I：
10.7150/jca.30731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015 at the First Affiliated Hospital of Fujian Medical University. Univariate and multivariate Cox regression analysis were used to explore the risk factors for progression to CRPC. Kaplan-Meier analysis and log-rank test were used to evaluate the difference in progression-free survival (PFS). Results: A total of 121 (56.0%) patients who underwent ADT showed progression to CRPC. Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients. Kaplan-Meier analysis demonstrated that patients in Gleason grade group >= 3, nPSA >0.2 ng/ml and TTN <6 months had shorter PFS. Conclusion: This study demonstrated that Gleason grade group, nPSA and TTN were risk factors for progression to CRPC. Patients with higher Gleason grade group, higher nPSA and shorter TTN have shorter PFS and higher risk of progression to CRPC after ADT.
引用
收藏
页码：5608 / 5613
页数：6
相关论文
共 27 条
[1]   A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer [J].
Amato, Robert ;
Stepankiw, Mika ;
Gonzales, Patricia .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) :1629-1634
[2]   Predicting the risk of bone metastasis in prostate cancer [J].
Briganti, Alberto ;
Suardi, Nazareno ;
Gallina, Andrea ;
Abdollah, Firas ;
Novara, Giacomo ;
Ficarra, Vincenzo ;
Montorsi, Francesco .
CANCER TREATMENT REVIEWS, 2014, 40 (01) :3-11
[3]   Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy [J].
Choueiri, Toni K. ;
Xie, Wanling ;
D'Amico, Anthony V. ;
Ross, Robert W. ;
Hu, Jim C. ;
Pomerantz, Mark ;
Taplin, Mary-Ellen ;
Kantoff, Philip W. ;
Sartor, Oliver ;
Oh, William K. .
CANCER, 2009, 115 (05) :981-987
[4]   Prostate cancer heterogeneity: Discovering novel molecular targets for therapy [J].
Ciccarese, Chiara ;
Massari, Francesco ;
Iacovelli, Roberto ;
Fiorentino, Michelangelo ;
Montironi, Rodolfo ;
Di Nunno, Vincenzo ;
Giunchi, Francesca ;
Brunelli, Matteo ;
Tortora, Giampaolo .
CANCER TREATMENT REVIEWS, 2017, 54 :68-73
[5]   EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].
Cornford, Philip ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Briers, Erik ;
De Santis, Maria ;
Gross, Tobias ;
Henry, Ann M. ;
Joniau, Steven ;
Lam, Thomas B. ;
Mason, Malcolm D. ;
van der Poel, Henk G. ;
van der Kwast, Theo H. ;
Rouviere, Olivier ;
Wiegel, Thomas ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2017, 71 (04) :630-642
[6]   Epidemiology, Etiology, Diagnosis and Treatment of Prostate Cancer [J].
Daniyal, Muhammad ;
Siddiqui, Zamir Ali ;
Akram, Muhammad ;
Asir, H. M. ;
Sultana, Sabira ;
Khan, Asmatullah .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (22) :9575-9578
[7]   Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data [J].
Delahunt, B. ;
Egevad, L. ;
Srigley, J. R. ;
Steigler, A. ;
Murray, J. D. ;
Atkinson, C. ;
Matthews, J. ;
Duchesne, G. ;
Spry, N. A. ;
Christie, D. ;
Joseph, D. ;
Attia, J. ;
Denham, J. W. .
PATHOLOGY, 2015, 47 (06) :520-525
[8]   Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer [J].
Divrik, Rauf Taner ;
Turkeri, Levent ;
Sahin, Ali F. ;
Akdogan, Bulent ;
Ates, Ferhat ;
Cal, Cag ;
Baltaci, Sumer .
UROLOGIA INTERNATIONALIS, 2012, 88 (01) :25-33
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival [J].
Facchini, Gaetano ;
Caffo, Orazio ;
Ortega, Cinzia ;
D'Aniello, Carmine ;
Di Napoli, Marilena ;
Cecere, Sabrina C. ;
Della Pepa, Chiara ;
Crispo, Anna ;
Mines, Francesca ;
Ruatta, Fiorella ;
Iovane, Gelsomina ;
Pisconti, Salvatore ;
Montella, Maurizio ;
Berretta, Massimiliano ;
Pignata, Sandro ;
Cavaliere, Carla .
FRONTIERS IN PHARMACOLOGY, 2016, 7
123